Table 1.
Characteristics of VAERS reports received following Tetanus toxoid, reduced diphtheria-toxoid, and acellular pertussis (Tdap) vaccine in pregnant women, United States, after Tdap vaccine was routinely recommended during pregnancy (October 2011- June 2015) (N=392)†
| Characteristic | |
|---|---|
| Tdap administered alonea, n (%) | 329 (83.9) |
| Maternal age in years, median (range)b | 29 (13-42) |
| Interval from vaccination to adverse event in days, median (range)c | 1 (0-255) |
| Gestational age in weeks at time of vaccination, median (range)d | 31.0 (1-41) |
| Reports of serious adverse events, n (%)e | 27 (6.9) |
| Trimester of pregnancy at time of vaccination (N=333)f, N (%) | |
| First (0 – 13 weeks) | 29 (8.7) |
| Second (14 – 27 weeks) | 40 (12.0) |
| Third (28 + weeks) | 264 (79.2) |
| Brand name of Tdap vaccine, N (%) | |
| Adacel | 234 (59.7) |
| Boostrix | 130 (33.2) |
| Unknown | 28 (7.1) |
| Type of reporter, N (%) | |
| Manufacturerg | 239 (60.9) |
| Provider | 85 (21.7) |
| Patient/parent | 49 (12.5) |
| Other | 19 (4.8) |
392 reports described 403 adverse events; 6 reports described maternal and infant outcomes; 107 (27.3%) reports originated in a single obstetrical practice.
Other vaccines given with Tdap included human papilloma virus vaccine (12;3.1%), and Tdap with meningococcal conjugate vaccine (7;1.8%).
Age was missing for 13pregnant woman.
Interval unknown for 11 reports.
Gestational age at time of vaccination is unknown for 61 reports.
A serious report is defined as such when one of the following is reported: death, life-threatening illness, hospitalization or prolongation of hospitalization, or permanent disability [12]
Trimester at time of vaccination is unknown for 58 reports.
In 197 (82.4%) reports submitted by the manufacturer, the reports originated from the provider